Recently, Yang Sheng, a member of the party group and deputy director of the State Drug Administration, led a research team to Nanjing and Suzhou, Jiangsu, to visit a number of innovative drug companies, learn more about the development progress of cutting-edge biological products and chemical innovative drug projects, and listen widely to opinions and suggestions. Yang Sheng stressed that it is necessary to seize development opportunities, focus on cutting-edge fields and key technologies, open up new tracks and models, accelerate breakthrough product research and development, and strive to create original first-launch varieties with high clinical value and strong international competitiveness. It is necessary to continue to deepen the reform of the review and approval system, optimize the central-local linkage model, improve the quality and efficiency of supervision services, increase support for innovative drug research and development, and promote the high-quality development of the biomedical industry.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.